The Legislative Approach and System Improvement of China’s Compulsory Licensing for Drug Patents

References

• WangR, GaoJ. IP Strategy for International Public Health Emergencies—Based on the Emergency Caused by COVID-19. China Invention & Patent. 2020;17(3):79–86.
   Google Scholar
• ZhengYD. Intellectual Property Countermeasures of Global Cooperation to Fight the COVID-19 (I). Electronics Intellectual Property. 2020;(4):73–84.
   Google Scholar
• KaplanM. The 2009 H1N1 Swine Flu pandemic: reconciling goals of patents and public health initiatives. Fordham Intellectual Property. Media Entertain Law J. 2010;20(3):991–1048.
   Google Scholar
• ChenLP. On the Legal regulation of patent abuse. Legal Forum. 2005;2:78–85.
   Google Scholar
• ChenX. The Relationship between technological innovation and patent System. Intellectual Prop Rights. 2019;64:79–87.
   Google Scholar
• LiuX. On Compulsory License of Drug Patent in Serious Emergent Public Health Crisis——Practical Necessity, Ethical Responses and Legal Arrangements. Electronics Intellectual Property. 2020;(4):63–72.
   Google Scholar
• LiuCQ, ZyZHAO.On the Derogation of Citizens’ Health Right in Emergencies and Its Limitations. Journal of Law Application. 2020;(9):30–39.
   Google Scholar
• TangQY, ZhuWQ, ShanSQ, GuXY, SuKY, ZhangJP. The Legislative Approach of Compulsory licensing of Drug patents in China. Chinese Journal of Nanfang Lunkan. 2020;(1):76–79.
   Google Scholar
• ZhangBS, ChenDD. International conflict and balance between drug patent protection and public right to health. Journal of Law Application. 2009;(12):73–76.
   Google Scholar
• PenroseET. The Economics of the International Patent System. Baltimore: Johns Hopkins Press; 1955.
   Google Scholar
• CaoL, LiuZ, ZhaoK, LiuYH.Review of the cases on the implementation of drug patent compulsory license from the international perspective. Chinese Journal of New Drugs. 2020;(13):1441–1448.
   Google Scholar
• AliF. Nexavar: the First Market-Initiated Compulsory License. NUJS Law Review. 2016;9(02):229–258.
   Google Scholar
• LiuLH, ZhaoJZ, ChenX, XieSM, WangT. Enlightenment of U.S. regulations regarding expanded access to investigational drugs and emergency use authorization. The Chinese Journal of Clinical Pharmacology. 2020;36(7):902–906+925.
   Google Scholar
• AntonyT. Rethinking TRIPS: ‘Adequate Remuneration’ for Non-voluntary Patent Licensing. J Int Econ Law. 2008;11(4):927–970. doi:10.1093/jiel/jgn035
   Web of Science ®Google Scholar
• HuangY. Impact of Tax Reform Act of 1986 on Foreign Investment. Law Science Magazine. 1989;(6):21–22.
   Google Scholar
• LiuLC, ZhuXZ. The Relative Connotation of “Public Health” for Drug Patent Compulsory License. Chinese Health Economics. 2015;34(02):73–78.
   Google Scholar
• TianXQ. Analysis on Legal Thoughts of the Encyclopedia School. POLITICAL SCIENCE AND LAW. 2010;(8):35–41.
   Google Scholar
• WangML, TanC. The Challenges and Responses:The Future of China’s Pharmaceutical Patent Regime:The Relationship between Pharmaceutical Patent and the Right to Health. Intellectual Property. 2017;(2):41–47.
   Google Scholar
• XuZX.The Conflict and Coordination between Right of Pharmaceutical Patent and Public Health. IIntellectual Property. 2011;(3):92–97.
   Google Scholar
• XiaoYD, SuJ. Public Health Crisis and the Compulsory License of Drug Patent. Science Technology and Law. 2010;(1):11–16.
   Google Scholar
• YangJB, LaiQY. The conflict and coordination between drug patent protection and public health protection. Heilongjiang Social Sciences. 2019;(5):120–124.
   Google Scholar
• ZhouYY. The Balance principle of administrative Discretion. Cass Journal of Law. 2004;(4):123–133.
   Google Scholar
• ZhouYX. On Medicine Patent and Public Health:View from Human Rights and Values Balancing Theory. Journal of Chengdu University of Technology(Social Sciences). 2007;(4):43–47.
   Google Scholar
• ChenC. Cheap Drugs ai What Price to Innovation: does the Compulsory Licensing of Pharmaceuticals Hurt Innovation. Berkeley Technology L J. 2003;18(1):55.
   Google Scholar
• KishoreK. Striking a Balance In Compulsory License Legislation. George Mason J Int Commercial Law. 2014;(1):241.
   Google Scholar
• LaurenceR. Human Rights and Intellectual Property: conflict or Coexistence. Netherlands Quarterly Human Rights. 2004;22(2):167–180. doi:10.1177/016934410402200202
   Google Scholar
• QianYL.A Jurisprudential Analysis of Forbidding Misuse of Rights. Modern Law Science. 2002;(1):55–61.
   Google Scholar
• QuSQ. On the Compulsory License of Patented Medicine and Public Health. Journal of Academic Exploration. 2006;(1):56–63.
   Google Scholar
• ZhangWJ, ZhangTL. TRIPS agreement and perfection of Compulsory patent License system in China. World Trade Organization Focus.2009;(6):24–29.
   Google Scholar
• ChenXY. On Classified Implementation of Drug Patent Compulsory License System in China ——From the Perspective of Supply Security of Generic Drug. Journal of Huaqiao University (Philosophy & Social Sciences). 2019;(5):99–110.
   Google Scholar
• QuSQ. On Public Health and the Compulsory License for Medicine Patent. Journal of Yunnan Nationalities University. 2007;(1):22–28.
   Google Scholar
• YuanJJ. Analysis on the Reasons for the Zero Implementation of Pharmaceutical Patent Compulsory License in China. Journal of Guangxi Administrative Cadre Institute of Politics and Law. 2019;34(4):90–95+116.
   Google Scholar
• HaoM. The Application of Compulsory Licensing of Medicine Patent in Developing Countries:From the Perspective of “Lu Yong” Case [J]. Intellectual Property. 2015;(8):95–101.
   Google Scholar
• LiCF. On the Defects and Improving Path of Compulsory License System for Pharmaceutical Patents in China. Administration and Law. 2019;(2):95–105.
   Google Scholar
• LiYQ. Development and thinking of compulsory drug patent licensing system. China Food Drug Administration. 2018;(8):14–21.
   Google Scholar
• JiangCY. Who Is the God of Medicine-Deciphering China’s Stance on Pharmaceutical Compulsory Licensing. Asian J WTO Int Health Law Policy. 2019;14(2):471–524.
   Web of Science ®Google Scholar
• BygbjergIC. Double Burden of Noncommunicable and Infectious Diseases in Developing Countries. Science. 2012;337(6101):1499–1501. doi:10.1126/science.122346622997329
   PubMed Web of Science ®Google Scholar
• GermanoS. Compulsory Licensing of Pharmaceuticals in Southeast Asia: paving the Way for Greater Use of the TRIPS Flexibility in Low-and Middle-Income Countries. UMKC Law Rev. 2007;76(1):273–294.
   Google Scholar
• RobertCB. Developing Nations and the Compulsory License: maximizing Access to Essential Medicines While Minimizing Investment Side Effects. J Law Med Ethics. 2009;37(2):209–221. doi:10.1111/j.1748-720X.2009.00366.x19493067
   PubMed Web of Science ®Google Scholar
• ChaudhryFI. Intellectual Property and the Global Crisis of Non-Communicable Disease. North Carolina J Law Tech. 2017;19(2):175–256.
   Google Scholar
• HoCM. Patent Breaking or Balancing: separating Strands of Fact from Fiction under Trips. North Carolina J Int Law Commercial Regulation. 2009;34(2):371–470.
   Google Scholar
• Kyung-BokS, Chang-yupK, Tae-JinL. Understanding of for whom, under what conditions and how the compulsory licensing of pharmaceuticals works in Brazil and Thailand: a realist synthesis. Glob Public Health. 2019;14(1):122–134. doi:10.1080/17441692.2018.147161329734843
   PubMed Web of Science ®Google Scholar
• MishkaG, AnnMM. Patients Versus Patents: Thailand and the Politics of Access to Pharmaceutical Products. J Third World Stud. 2010;27(1):215–234.
   Google Scholar
• JakkritK. Compulsory Licenses: law and Practice in Thailand. MPI Studies Intellectual Property Competition Law. 2015;22:61–77.
   Google Scholar
• RichardGE, LamDK. Balancing Trade in Patents: public Non-Commercial Use and Compulsory Licensing. J World Intellectual Property. 2003;6(1):5–32.
   Google Scholar
• BetsyVR. India’s first compulsory license over Bayer’s patent. J Intellectual Property Law Practice. 2012;7(7):482–484. doi:10.1093/jiplp/jps075
   Google Scholar
• FengJH. Compulsory licensing of pharmaceutical patents: development after Doha Declaration on Health. J Wuhan Univ. 2008;1(5):700–705.
   Google Scholar
• ReedB, RandallK. Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: a Database Analysis. PLoS Med. 2012;9(1):1–9.
   Web of Science ®Google Scholar
• ChenYF, LeiY, WuL. The Drug Patent Compulsory Licensing System in India and Its Empirical Study. Price:Theory & Practice. 2018;(8):90–93.
   Google Scholar
• ZhouLL, TianK, YaoYY, et al. India’s Compulsory Licensing System for Drug Patents and Its Enlightenment to China. Journal of Nanjing University of Traditional Chinese Medicine(Social Science Edition). 2019;20(1):58–62.
   Google Scholar
• DevikaA, RadhikaA. Indian Patent Office rejects Saxagliptin compulsory license application. J Intellectual Property Law Practice. 2016;11(8):565–566. doi:10.1093/jiplp/jpw064
   Google Scholar
• KinneyED, ClarkBA. Provisions for Health and Health Care in the Constitutions of the Countries of the World. Cornell Int Law J. 2004;37(2):285–356.
   Web of Science ®Google Scholar
• LazzariniZ. Making Access to Pharmaceuticals a Reality: legal Options under TRIPS and the Case of Brazil. Yale Human Rights Dev Law J. 2003;6:103–138.
   Google Scholar
• SamiraG. Evaluating the usefulness of compulsory licensing in developing countries: a comparative study of Thai and Brazilian experiences regarding access to AIDS treatments. Dev World Bioeth. 2017;17(2):90–99. doi:10.1111/dewb.1212427699996
   PubMed Web of Science ®Google Scholar
• VarellaMD. The WTO, Intellectual Property and AIDS: case Studies from Brazil and South Africa. J World Intellectual Property. 2004;7(4):523–548. doi:10.1111/j.1747-1796.2004.tb00218.x
   Google Scholar
• ArmoutiW. Grounds for Compulsory License with Selected Cases Granted for Pharmaceuticals. Tulane J Int Comparative Law. 2018;26(2):381–404.
   Google Scholar
• HuangLP. On the deficiency and improvement of China’s current compulsory drug patent licensing legislation. J Law. 2012;33(5):92–97.
   Google Scholar
• YanN, LiL. Consideration on the Improvement of the Drug Patent Compulsory License. China Invention & Patent. 2017;9:42–45
   Google Scholar
• ZhaoL. Implementation to Compulsory License System of the Pharmaceutical Patent in China. Tribune of Political Science and Law. 2017;(2):146–151.
   Google Scholar
• LinXQ. The Improvement of Patent Compulsory License system in China. CHINESE JOURNAL OF LAW. 2006;(6):30–38.
   Google Scholar
• WangQ. On the application of proportionality principle in compulsory patent license – taking the compulsory patent license of medicine under TRIPs as an example. Chine Health Law. 2019;27(3):50–57.
   Google Scholar
• BaleHE. Patent Protection and Pharmaceutical Innovation. N Y Univ J Int Law Politics. 1996;29(1&2):95–108.
   Google Scholar
• CameronD. License To Pill: compulsory Licensing As A Solution To Drug Over-Pricing. Nexus. 2016;21:47–66.
   Google Scholar
• FerroneJD. Compulsory licensing during public health crises: bioterrorism’s mark on global pharmaceutical patent protection. Suffolk Transnatl Law R. 2003;26(2):385–410.
   Google Scholar